SCHEDULE: Vanguard Group Discloses 6.74% Stake in Travere Therapeutics

The Vanguard Group has filed an amended Schedule 13G, reporting a 6.74% beneficial ownership stake in Travere Therapeutics Inc. as of June 30, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 5,994,283 shares of Travere Therapeutics Inc. common stock.
• This represents 6.74% of the company's outstanding common stock.
• Vanguard holds sole dispositive power over 5,806,026 shares and shared dispositive power over 188,257 shares.
• Vanguard has shared voting power over 107,100 shares and no sole voting power.
• The filing was made as an investment adviser (IA) in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a substantial passive investment by The Vanguard Group, a major institutional investor, in Travere Therapeutics. This significant stake (6.74%) suggests a positive long-term view from Vanguard's perspective, as such large holdings are typically made with confidence in the underlying company's value proposition.

Positives

• A major institutional investor like The Vanguard Group holding a significant stake (6.74%) can signal confidence in Travere Therapeutics' long-term prospects.
• Vanguard's investment is held in the ordinary course of business, indicating a passive investment strategy rather than an activist one.

Future Outlook

The filing, a Schedule 13G, is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Travere Therapeutics' future performance or outlook.

Management Comments

• The Vanguard Group's clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.
• No one other person's interest in the securities reported herein is more than 5%.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

This Schedule 13G filing indicates a significant passive investment by a major asset manager, The Vanguard Group, in Travere Therapeutics. Such filings are common for large institutional investors who cross a 5% ownership threshold in a public company, reflecting their portfolio allocation decisions rather than active management or strategic influence over the company's operations. It provides transparency into significant institutional holdings within the biotechnology or pharmaceutical sector, where Travere Therapeutics likely operates.

Stakeholder Impact

• Shareholders: Increased transparency regarding a major institutional holder, potentially boosting confidence due to Vanguard's reputation and passive investment strategy.
• Company Management: Awareness of a significant passive shareholder, which typically does not seek to influence management decisions.

Key Dates

Keywords

Travere Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals